madman
Super Moderator
PROFOUND, SUSTAINED WEIGHT LOSS IN MEN WITH FUNCTIONAL HYPOGONADISM RECEIVING 13 YEARS OF LONG-TERM TESTOSTERONE THERAPY - CLINICAL EXPERIENCE OF 8,190 PATIENTYEARS (2022)
Karim Haider, Ahmad Haider, Gheorghe Doros, Abdulmaged Traish Private Urology Practice, Bremerhaven, Germany; Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA; Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, MA, USA
Introduction and Objectives: Testosterone therapy (TTh) is addressed in AACE Guidelines as an approach to treating obesity in hypogonadal men. No other guidelines followed their recommendations. We investigated the effects of TTh over 13 years and updated our study results.
Methods: In a registry of 796 men with symptomatic functional hypogonadism, 394 men (49.5%) received testosterone therapy (TTh) by testosterone undecanoate (TU) injections of 1000mg/12weeks following an initial 6-week interval (T-group). 402 men opted against TTh and served as controls (CTRL). 13-year data are presented. Means and standard deviations of absolute measures over 13 years are reported.
Results: Mean age at baseline: 60.9±6.0 years (T-group: 58.5±6.3, CTRL: 63.2±4.8). Mean (median) follow-up: T-group 10.1±3.0(11), CTRL 10.5±3.0(12) years.
*Waist circumference (cm) decreased from 110.9±13.7 to 96.1±5.1 in the T- group (p<0.0001) and increased in CTRL from 111.0±11.8 to 114.3±8.3 (p<0.0001). Difference between groups at 13 years: 20.2 (p<0.0001).
*Weight (kg) decreased from 106.6±17.1 to 84.7±7.7 (T-group) (p<0.0001) and increased (CTRL) from 95.3±13.4 to 98.5±9.8 (p<0.0001). Difference between groups: 18.2 (p<0.0001).
*BMI (kg/m²) decreased from 34.2±5.4 to 27.5±2.4 in the T-group (p<0.0001) and increased in CTRL from 30.5±4.4 to 31.6±3.4 (p<0.0001). Difference between groups: 5.7 (p<0.0001).
*Weight change from baseline was -19.3±8.0% in the T-group and 9.6±3.5% in CTRL (p<0.0001 for both). Difference between groups: -28.5% (p<0.0001).
*Waist:height ratio decreased from 0.63±0.08 to 0.55±0.03 in the T-group and increased from 0.63±0.07 to 0.65±0.05) in CTRL (p<0.0001 for both). Difference between groups: 0.11 (p<0.0001).
*Visceral adiposity index (VAI) decreased from 5.1±2.5 to 1.9±0.4 in the T- group and increased from 4.3±2.2 to 7.6±3.6 in CTRL (p<0.0001 for both). Difference between groups: 6.2 (p<0.0001). Adherence to testosterone was 100% as injections were administered in the office and documented
Conclusion: Men with hypogonadism receiving TTh had profound, sustained improvements in anthropometric parameters over 13 years. Untreated men gained weight.
Karim Haider, Ahmad Haider, Gheorghe Doros, Abdulmaged Traish Private Urology Practice, Bremerhaven, Germany; Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA; Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, MA, USA
Introduction and Objectives: Testosterone therapy (TTh) is addressed in AACE Guidelines as an approach to treating obesity in hypogonadal men. No other guidelines followed their recommendations. We investigated the effects of TTh over 13 years and updated our study results.
Methods: In a registry of 796 men with symptomatic functional hypogonadism, 394 men (49.5%) received testosterone therapy (TTh) by testosterone undecanoate (TU) injections of 1000mg/12weeks following an initial 6-week interval (T-group). 402 men opted against TTh and served as controls (CTRL). 13-year data are presented. Means and standard deviations of absolute measures over 13 years are reported.
Results: Mean age at baseline: 60.9±6.0 years (T-group: 58.5±6.3, CTRL: 63.2±4.8). Mean (median) follow-up: T-group 10.1±3.0(11), CTRL 10.5±3.0(12) years.
*Waist circumference (cm) decreased from 110.9±13.7 to 96.1±5.1 in the T- group (p<0.0001) and increased in CTRL from 111.0±11.8 to 114.3±8.3 (p<0.0001). Difference between groups at 13 years: 20.2 (p<0.0001).
*Weight (kg) decreased from 106.6±17.1 to 84.7±7.7 (T-group) (p<0.0001) and increased (CTRL) from 95.3±13.4 to 98.5±9.8 (p<0.0001). Difference between groups: 18.2 (p<0.0001).
*BMI (kg/m²) decreased from 34.2±5.4 to 27.5±2.4 in the T-group (p<0.0001) and increased in CTRL from 30.5±4.4 to 31.6±3.4 (p<0.0001). Difference between groups: 5.7 (p<0.0001).
*Weight change from baseline was -19.3±8.0% in the T-group and 9.6±3.5% in CTRL (p<0.0001 for both). Difference between groups: -28.5% (p<0.0001).
*Waist:height ratio decreased from 0.63±0.08 to 0.55±0.03 in the T-group and increased from 0.63±0.07 to 0.65±0.05) in CTRL (p<0.0001 for both). Difference between groups: 0.11 (p<0.0001).
*Visceral adiposity index (VAI) decreased from 5.1±2.5 to 1.9±0.4 in the T- group and increased from 4.3±2.2 to 7.6±3.6 in CTRL (p<0.0001 for both). Difference between groups: 6.2 (p<0.0001). Adherence to testosterone was 100% as injections were administered in the office and documented
Conclusion: Men with hypogonadism receiving TTh had profound, sustained improvements in anthropometric parameters over 13 years. Untreated men gained weight.
